BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 28790381)

  • 21. A variant of exotoxin A that forms potent and specific chemically conjugated immunotoxins.
    Chaudry GJ; Fulton RJ; Draper RK
    J Biol Chem; 1993 May; 268(13):9437-41. PubMed ID: 8486636
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cytotoxic effect of ricin A-chain conjugates containing monoclonal antibodies against human erythroid cells.
    Tonevitsky AG; Agapov II; Ershova GV; Sarma T; Toptygin AYu ; Mechetner EB
    Int J Immunopharmacol; 1993 Feb; 15(2):229-35. PubMed ID: 8468120
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Monoclonal antibodies recognising the cluster 2 antigen associated with human small cell lung cancer mediate the toxic effects of ricin A chain in an indirect assay of immunotoxin cytotoxicity.
    Derbyshire EJ; Wawrzynczak EJ
    Br J Cancer Suppl; 1991 Jun; 14():74-7. PubMed ID: 1645578
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunotoxins constructed with chimeric, short-lived anti-CD22 monoclonal antibodies induce less vascular leak without loss of cytotoxicity.
    Liu XY; Pop LM; Schindler J; Vitetta ES
    MAbs; 2012; 4(1):57-68. PubMed ID: 22327430
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recombinant ricin A chain conjugated to monoclonal antibodies: improved tumor cell inhibition in the presence of lysosomotropic compounds.
    Ramakrishnan S; Bjorn MJ; Houston LL
    Cancer Res; 1989 Feb; 49(3):613-7. PubMed ID: 2783383
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anti-CD6-blocked ricin: an anti-pan T-cell immunotoxin.
    Collinson AR; Lambert JM; Liu Y; O'Dea C; Shah SA; Rasmussen RA; Goldmacher VS
    Int J Immunopharmacol; 1994 Jan; 16(1):37-49. PubMed ID: 8150554
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting of an activated T-cell subset using a bispecific antibody-toxin conjugate directed against CD4 and CD26.
    Duke-Cohan JS; Morimoto C; Schlossman SF
    Blood; 1993 Oct; 82(7):2224-34. PubMed ID: 8104537
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A novel method to purify immunotoxins from free antibodies using modified recombinant toxins.
    Dhanabal M; Fryxell DK; Ramakrishnan S
    J Immunol Methods; 1995 Jun; 182(2):165-75. PubMed ID: 7790724
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunotoxins up to the present day.
    Drobniewski FA
    Biosci Rep; 1989 Apr; 9(2):139-56. PubMed ID: 2669993
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of the cytotoxic activity of the immunotoxins with different internalization rate.
    Tonevitsky AG; Agapov II; Mechetner EB; Ershova GV; Toptygin AYu ; Sarma T; Shamshiev AT; Pfueller U
    Biochem Mol Biol Int; 1993 Dec; 31(6):1059-69. PubMed ID: 8193589
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antibody-mediated inhibition of ricin toxin retrograde transport.
    Yermakova A; Klokk TI; Cole R; Sandvig K; Mantis NJ
    mBio; 2014 Apr; 5(2):e00995. PubMed ID: 24713323
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Diverse recombinant HIV-1 Envs fail to activate B cells expressing the germline B cell receptors of the broadly neutralizing anti-HIV-1 antibodies PG9 and 447-52D.
    McGuire AT; Glenn JA; Lippy A; Stamatatos L
    J Virol; 2014 Mar; 88(5):2645-57. PubMed ID: 24352455
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ricin A-chain containing immunotoxins directed against different epitopes on the CD2 molecule differ in their ability to kill normal and malignant T cells.
    Press OW; Martin PJ; Thorpe PE; Vitetta ES
    J Immunol; 1988 Dec; 141(12):4410-7. PubMed ID: 2461993
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Characterization of a stable HIV-1 B/C recombinant, soluble, and trimeric envelope glycoprotein (Env) highly resistant to CD4-induced conformational changes.
    Kumar R; Ozorowski G; Kumar V; Holden LG; Shrivastava T; Patil S; Deshpande S; Ward AB; Bhattacharya J
    J Biol Chem; 2017 Sep; 292(38):15849-15858. PubMed ID: 28743743
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Resistance of myeloid leukaemia cell lines to ricin A-chain immunotoxins.
    Engert A; Brown A; Thorpe P
    Leuk Res; 1991; 15(11):1079-86. PubMed ID: 1961012
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Selective cytotoxic effect of an immunotoxin on human erythroid tumor cells].
    Tonevitskiĭ AG; Agapov II; Mechetner EB
    Mol Biol (Mosk); 1991; 25(5):1181-7. PubMed ID: 1753950
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Selective cytotoxicity of antibody-ricin-A-chain conjugate for human tumor B cells. II. Comparison of activity of immunotoxins conjugated with poly- and monoclonal antibodies].
    Tonevitskiĭ AG; Zhukova OS; Rakhmanova VA; Arsen'eva EL; Bogacheva GT
    Mol Biol (Mosk); 1988; 22(4):911-6. PubMed ID: 3141780
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Specific killing of HIV-infected lymphocytes by a recombinant immunotoxin directed against the HIV-1 envelope glycoprotein.
    Bera TK; Kennedy PE; Berger EA; Barbas CF; Pastan I
    Mol Med; 1998 Jun; 4(6):384-91. PubMed ID: 10780881
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of protein synthesis inhibition kinetics and cell killing induced by immunotoxins.
    Sung C; Wilson D; Youle RJ
    J Biol Chem; 1991 Aug; 266(22):14159-62. PubMed ID: 1860832
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recombinant hybrid toxin with dual enzymatic activities. Potential use in preparing highly effective immunotoxins.
    Li BY; Ramakrishnan S
    J Biol Chem; 1994 Jan; 269(4):2652-8. PubMed ID: 8300596
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.